卡瑞利珠单抗联合化疗在局部晚期食管鳞癌转化治疗中的应用  

The study of conversion therapy with carrelizumab combined with chemotherapy in unresectable locally advanced esophageal cancer

作　　者：田文泽[1] 熊新魁 徐达夫[1] 胡忠吾[1] 蒋超 尤振兵[1] 赵建强[1] 徐克平[1] TIAN Wenze;XIONG Xinkui;XU Dafu(Department of Thoracic Surgery,the Afiliated Huai'an No.1People's Hospital of Nanjing Medical University,Huai'an 223300,China)

机构地区：[1]南京医科大学附属淮安第一医院胸外科,233000 [2]南京医科大学附属淮安第一医院肿瘤内科,233000

出　　处：《临床外科杂志》2022年第8期741-743,共3页Journal of Clinical Surgery

基　　金：国家自然科学青年基金(82102969)。

摘　　要：目的 探讨卡瑞利珠单抗联合化疗在初治不可切除的局部晚期食管癌转化治疗中的应用价值。方法 我院2020年2月~2021年12月收治初治不可切除的局部晚期食管鳞癌病人行转化治疗22例,采用描述性病例系列研究。术前予以卡瑞利珠单抗+白蛋白紫杉醇+顺铂方案行3~4周期治疗;经多学科联合会诊后评估为可R0切除的病人行手术治疗。分析病人转化治疗的效果、不良反应及手术情况。结果 经免疫联合化疗的诱导治疗后,22例病人中有6例完全缓解、14例部分缓解,客观缓解率为90.91%(20/22);16例病人经转化治疗后选择行手术治疗,手术转化率为72.73%(16/22);R0手术切除率为93.75%(15/16)。结论 卡瑞利珠单抗联合化疗在初治局部晚期不可切除食管癌转化治疗中可以获得较好的临床缓解和较高的手术转化率。Objective To investigate the value of carrelizumab combined with chemotherapy in conversion therapy of primary unresectable locally advanced esophageal cancer.Methods A descriptive case series study was used to retrospectively analyze 22 patients with unresectable locally advanced esophageal squamous cell carcinoma who underwent conversion therapy from February 2020 to December 2021.They were treated with “carrelizumab + albumin paclitaxel+cisplatin” regimen for 3-4 cycles before operation.The patients who were evaluated as radical surgery after multidisciplinary joint consultation were treated with surgery.The effect, adverse reactions and surgical index during conversion therapy were analyzed.Results After conversion therapy, Among the 22 patients, 6 had complete remission and 14 had partial remission.The objective remission rate was 90.91%(20/22);16 patients underwent surgery after transformation.The conversion rate was 72.73%(16/22);The resection rate of R0 was 93.75%(15/16).Conclusion Carrelizumab combined with chemotherapy can achieve better clinical remission and higher R0 resection in the conversion therapy of primary advanced unresectable esophageal cancer.

关 键 词：食管癌 转化治疗 免疫治疗 化疗 

分 类 号：R735.1[医药卫生—肿瘤]